Asquith Justin M, Copacia Jessica, Mogul Mark J, Bajwa Rajinder P S
Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA.
Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Pediatr Transplant. 2015 Sep;19(6):E157-9. doi: 10.1111/petr.12547. Epub 2015 Jun 23.
For patients with DBA who are transfusion dependent, HSCT is the only cure. Chronic transfusions can lead to cirrhosis secondary to iron overload, making them poor candidates for myeloablative HSCT. RIC regimens are associated with lower morbidity and mortality compared to myeloablative regimens, but use of RIC in DBA has been limited. Here we present a 14-yr-old girl with DBA and multiple comorbidities including liver cirrhosis, who underwent MUD HSCT utilizing a RIC regimen that is novel to this condition. She tolerated the regimen well, and at 21 months, she remains transfusion independent with chimerisms at 99%.
对于依赖输血的先天性纯红细胞再生障碍性贫血(DBA)患者,异基因造血干细胞移植(HSCT)是唯一的治愈方法。长期输血可导致铁过载继发肝硬化,这使得他们不适合进行清髓性HSCT。与清髓性方案相比,减低强度预处理(RIC)方案的发病率和死亡率较低,但RIC在DBA中的应用一直有限。在此,我们报告一名14岁患有DBA并伴有多种合并症(包括肝硬化)的女孩,她接受了单倍体相合造血干细胞移植(MUD HSCT),采用了针对这种情况的新型RIC方案。她对该方案耐受性良好,在21个月时,她仍无需输血,嵌合率达99%。